Illumina Newsroom

Myriad Genetics Announces The Incorporation Of Its HRD Platform In Illumina's Updated Gene Panel Assay

BenzingaNov 21 05:33

Myriad Genetics Announces Incorporation of Its Proprietary HRD Platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 V2

Globe NewswireNov 21 05:30

If RFK Jr. Cuts Science Funding, These Instrument Makers May Suffer -- Barrons.com

Barron'sNov 21 04:29

Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)

Earnings Call TranscriptsNov 21 03:09

Because Minna announced the expansion of the TruSight Oncology product line.

The latest solution will be unveiled at the annual meeting of the Molecular Pathology Association to achieve a comprehensive mutation analysis of tumors. Research and sharing led by Illumina customers will provide the latest evidence and related content for tumor analysis. San Diego, California, USA, November 20, 2024 / PRNewswire / -- Illumina Inc. (NASDAQ: ILMN), a leader in global DNA sequencing and chip technology, today announced the launch of a new version of its flagship cancer research testing product, TruSight Oncology 500 v2 (TSO 500 v2), for

PR NewswireNov 20 10:00

Express News | Illumina Inc: Trusight Oncology 500 V2 Assay Is Currently Under Development, Global Release Planned for Mid-2025

BreakingsNov 19 22:16

Express News | Illumina Announces Expansion of Trusight Oncology Portfolio

BreakingsNov 19 22:15

Illumina Announces Expansion of TruSight Oncology Portfolio

PR NewswireNov 19 22:15

Is Illumina, Inc. (ILMN) the Best Immunotherapy Stock to Buy Now?

Yahoo FinanceNov 18 22:16

Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness

Seeking AlphaNov 16 04:55

Citi Maintains Illumina(ILMN.US) With Buy Rating, Maintains Target Price $190

Futu NewsNov 14 19:31 · Ratings

Illumina Coverage Resumed at Equal Weight by Morgan Stanley

Seeking AlphaNov 13 04:13

ARKK's Holdings Ranked by SA Quant Grades

Seeking AlphaNov 13 03:21

Stephens Maintains Illumina(ILMN.US) With Buy Rating, Raises Target Price to $184

Futu NewsNov 12 20:31 · Ratings

Stephens & Co. Maintains Overweight on Illumina, Raises Price Target to $184

BenzingaNov 12 20:30 · Ratings

Morgan Stanley Maintains Illumina(ILMN.US) With Hold Rating, Cuts Target Price to $156

Futu NewsNov 12 19:31 · Ratings

Illumina, Inc. (ILMN): Unlocking Growth Potential in Genetic Testing and Robotics

Yahoo FinanceNov 12 12:59

Illumina Is Maintained at Overweight by Piper Sandler

Dow JonesNov 11 21:05 · Ratings

Piper Sandler Maintains Illumina(ILMN.US) With Buy Rating, Cuts Target Price to $185

Futu NewsNov 11 20:34 · Ratings

Express News | Illumina Inc : Piper Sandler Cuts Target Price to $185 From $195

BreakingsNov 11 12:16